Xenetic Biosciences Q4 EPS $(0.22) Beats $(0.52) Estimate, Sales $766.296K Beat $690.000K Estimate

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.52) by 57.69 percent. This is a 67.65 percent increase over losses of $(0.68) per share from the same period last year. The company reported quarterly sales of $766.296 thousand which beat the analyst consensus estimate of $690.000 thousand by 11.06 percent. This is a 18.11 percent increase over sales of $648.820 thousand the same period last year.